Monitoring After CAR-T Therapy for Multiple Myeloma: The APP Perspective

In this latest episode of ASTCT Talks, Rahul Banerjee interviews Josh Epworth, a lead nurse practitioner in the plasma cell disorders clinic at the Fred Hutchinson Cancer Center. They delve into the topic of monitoring after CAR-T therapy for multiple myeloma. Mr. Epworth shares insights from his experience in the outpatient setting, discussing issues like hypogammaglobulinemia, immune cell functionality, and infections that may arise after CAR-T treatment. They also touch on monitoring for cytomegalovirus (CMV) and other respiratory viruses, as well as the importance of developing close relationships with local healthcare providers to ensure patients receive timely care.

About Josh Epworth, MSN, ARNP
Josh Epworth is a Nurse Practitioner at the Fred Hutchinson Cancer Center (FHCC) and is a Teaching Associate at the University of Washington School of Medicine. He is board-certified in Adult/Gerontology medicine and specializes in the treatment of multiple myeloma. As a staff member of FHCC’s multiple myeloma team, Mr. Epworth is involved in disease treatment, symptom management, patient education and clinical trials.

About Dr. Rahul Banerjee, MD, FACP
Dr. Banerjee, MD, FACP, (@RahulBanerjeeMD) is an Assistant Professor in the Division of Medical Oncology at the University of Washington and at the Fred Hutchinson Cancer Center. Prior to moving to Seattle, he completed his hematology/oncology fellowship and advanced fellowship in BMT/CAR-T therapy at the University of California San Francisco. His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience.

This episode was sponsored by Janssen Oncology and Legend Biotech.